AZD5213 + AZD5213 + AZD5213

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Mild Cognitive Impairment

Conditions

Mild Cognitive Impairment, Mild Alzheimer's Disease

Trial Timeline

Apr 1, 2012 → Jan 1, 2013

NCT ID

NCT01548287

About AZD5213 + AZD5213 + AZD5213

AZD5213 + AZD5213 + AZD5213 is a phase 2 stage product being developed by AstraZeneca for Mild Cognitive Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT01548287. Target conditions include Mild Cognitive Impairment, Mild Alzheimer's Disease.

What happened to similar drugs?

8 of 17 similar drugs in Mild Cognitive Impairment were approved

Approved (8) Terminated (2) Active (8)

✅Aricept (donepezil hydrochloride) + placeboEisaiApproved

✅Donepezil HClEisaiApproved

✅ElagolixAbbVieApproved

✅Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcgAstraZenecaApproved

✅Aliskiren + Hydrochlorothiazide + AmlodipineNovartisApproved

✅Rivastigmine PatchNovartisApproved

✅ElidelBayerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01548287	Phase 2	Completed	Apr 1, 2012	Jan 1, 2013	Mild Cognitive Impairment

Competing Products

20 competing products in Mild Cognitive Impairment

See all competitors

Product	Company	Stage	Hype Score
Neurosteroid enantiomer	Oragenics	Phase 2	32
Ranirestat + Placebo	Eisai	Phase 2/3	38
Aricept (donepezil hydrochloride) + placebo	Eisai	Approved	43
Donepezil HCl	Eisai	Approved	43
Donanemab + Aducanumab	Eli Lilly	Phase 3	40
PPAR alpha + Hydrochlorothiazide + Placebo	Eli Lilly	Phase 2	35
Elagolix	AbbVie	Approved	35
AZD1446 + Placebo	AstraZeneca	Phase 2	35
MEDI1814 for IV injection + MEDI1814 for Subcutaneous Injection + IV Placebo + Placebo for Subcutaneous Injection	AstraZeneca	Phase 1	29
Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcg	AstraZeneca	Approved	43
budesonide/formoterol (Symbicort)	AstraZeneca	Phase 3	40
MK-8931	Merck	Phase 1	29
Montelukast to placebo + Placebo to montelukast	Merck	Pre-clinical	26
Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2)	Merck	Phase 3	32
Aliskiren + Hydrochlorothiazide + Amlodipine	Novartis	Approved	43
LCZ696 + Sildenafil	Novartis	Phase 2	35
QCZ484 + Placebo	Novartis	Phase 1	29
Rivastigmine Patch	Novartis	Approved	43
AFQ056	Novartis	Phase 1	29
Canakinumab	Novartis	Phase 2	27